DBIBB

CAS No. 1569309-92-7

DBIBB( —— )

Catalog No. M33784 CAS No. 1569309-92-7

DBIBB is a non-lipid agonist of specific lysophosphatidic acid (LPA2) type 2 G-protein-coupled receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 53 Get Quote
5MG 81 Get Quote
10MG 129 Get Quote
25MG 255 Get Quote
50MG 365 Get Quote
100MG 525 Get Quote
500MG 1053 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    DBIBB
  • Note
    Research use only, not for human use.
  • Brief Description
    DBIBB is a non-lipid agonist of specific lysophosphatidic acid (LPA2) type 2 G-protein-coupled receptor.
  • Description
    DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    LPA Receptor
  • Recptor
    LPA Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1569309-92-7
  • Formula Weight
    452.48
  • Molecular Formula
    C23H20N2O6S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (221.00 mM )
  • SMILES
    OC(=O)c1ccccc1S(=O)(=O)NCCCCN1C(=O)c2cccc3cccc(C1=O)c23
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Patil R, et al. Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist. Chem Biol. 2015;22(2):206-216.?
molnova catalog
related products
  • LPA1 receptor antago...

    LPA1 receptor antagonist 1(LPA1 R antagonist 1) is a selective and potent lysophosphatidic acid (LPA1) receptor antagonist (IC50 : 25 nM) for the study of idiopathic pulmonary fibrosis.

  • TAK-615

    TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors.

  • Radioprotectin-1

    Radioprotectin-1 is a selective agonist of LPA2 with EC50 of 25 nM for murine LPA2 GPCR and exerts radioprotective and radiomitigative action.